CMS Launches Medicare GLP-1 Bridge for Certain Medicare Part D Beneficiaries
Our Privacy Policy has been updated! The Conference Board uses cookies to improve our website, enhance your experience, and deliver relevant messages and offers about our products. Detailed information on the use of cookies on this site is provided in our cookie policy. For more information on how The Conference Board collects and uses personal data, please visit our privacy policy. By continuing to use this Site or by clicking “ACCEPT”, you acknowledge our privacy policy and consent to the use of cookies. Our Privacy Policy has been updated! Detailed information on the use of cookies on this site is provided in our cookie policy and our privacy policy.
Loading…
The CEO Center Newsletters & Policy Alerts
CMS Launches Medicare GLP-1 Bridge for Certain Medicare Part D Beneficiaries
08 July 2026 /
Newsletters & Alerts
Download
Policy Alert
Action: On July 1, the Centers for Medicare & Medicaid Services (CMS) launched Medicare GLP-1 Bridge,1 a demonstration program that will provide eligible Medicare beneficiaries access to certain GLP-1 medications for weight management at a $50 monthly copay through December 31, 2027. The program is separate from the standard Medicare Part D benefit
Trusted Insights for What’s Ahead®
- GLP-1 drugs have demonstrated clinical value but remain expensive, raising broader questions about program costs and long-term use and outcomes.2 Most private plans do not cover use of GLP-1 drugs for weight loss; those that do generally include strict prior authorization and other requirements (such as high Body Mass Index scores and comorbidities and proof of weight loss).3
- This temporary program expands access to GLP-1 medications for beneficiaries who seek treatment to reduce excess body weight or maintain weight reduction but would not otherwise have access to these drugs through Part D. Eligible products currently include Foundayo®, Wegovy®, and Zepbound® KwikPen®.
- Beneficiaries will pay a fixed $50 copay that does not count toward Part D out-of-pocket costs. CMS also states that participating manufacturers will provide eligible GLP-1 drugs at a net (and presumably negotiated) price of $245 per monthly supply, meaning Medicare will cover over 80% of the cost.
- Eligibility is targeted. Beneficiaries must meet clinical criteria based on body mass index (BMI) and, in some cases, qualifying conditions such as cardiovascular disease, kidney disease, prediabetes, prior stroke, or uncontrolled hypertension. An analysis based on 2023 claims data estimates that nearly 4 million Part D beneficiaries could be eligible.4
- Drugs used for weight loss, including anti-obesity medications, are generally excluded from Medicare. However, GLP-1 drugs are covered for Medicare when prescribed for diabetes, cardiovascular risk reduction, obstructive sleep apnea, or liver disease. The demonstration permits CMS to gather utilization data to inform future policy, including other innovation models being tested to pair negotiated GLP-1 access with nutrition and physical activity supports.5
- CMS hopes greater use of these drugs for weight management will lead to savings in the program over time as beneficiaries are healthier.
- CMS is setting guardrails to prevent the program from becoming a substitute for Part D coverage. Beneficiaries with Part D-coverable indications are excluded, and Part D plans must maintain normal coverage, formulary exception, and appeal processes. CMS will monitor Part D and Bridge data for inappropriate cost shifting, including plan practices that deny, limit, or redirect coverage to avoid Part D responsibility.
- What this means for business:
- GLP-1s are a major health benefits issue across public and private markets. Survey data of employers shows concern that GLP-1s are contributing to rising health care costs.6 As public programs test new approaches to GLP-1 access and pricing, the impact will likely shift to private plans as well, particularly if the demonstration project succeeds and becomes the basis for new CMS policy.
- https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program
- https://www.healthline.com/health/drugs/will-my-insurance-cover-glp-1-for-weight-loss#private-insurance-coverage
- https://www.kff.org/medicare/nearly-four-million-medicare-beneficiaries-could-be-eligible-for-the-temporary-medicare-glp-1-bridge-program-covering-these-drugs-for-weight-loss/
- https://www.cms.gov/priorities/innovation/innovation-models/balance
- https://www.businessgrouphealth.org/newsroom/news-and-press-releases/press-releases/2026-glp-1-survey
Action: On July 1, the Centers for Medicare & Medicaid Services (CMS) launched Medicare GLP-1 Bridge,1 a demonstration program that will provide eligible Medicare beneficiaries access to certain GLP-1 medications for weight management at a $50 monthly copay through December 31, 2027. The program is separate from the standard Medicare Part D benefit
Trusted Insights for What’s Ahead®
- GLP-1 drugs have demonstrated clinical value but remain expensive, raising broader questions about program costs and long-term use and outcomes.2 Most private plans do not cover use of GLP-1 drugs for weight loss; those that do generally include strict prior authorization and other requirements (such as high Body Mass Index scores and comorbidities and proof of weight loss).3
- This temporary program expands access to GLP-1 medications for beneficiaries who seek treatment to reduce excess body weight or maintain weight reduction but would not otherwise have access to these drugs through Part D. Eligible products currently include Foundayo®, Wegovy®, and Zepbound® KwikPen®.
- Beneficiaries will pay a fixed $50 copay that does not count toward Part D out-of-pocket costs. CMS also states that participating manufacturers will provide eligible GLP-1 drugs at a net (and presumably negotiated) price of $245 per monthly supply, meaning Medicare will cover over 80% of the cost.
- Eligibility is targeted. Beneficiaries must meet clinical criteria based on body mass index (BMI) and, in some cases, qualifying conditions such as cardiovascular disease, kidney disease, prediabetes, prior stroke, or uncontrolled hypertension. An analysis based on 2023 claims data estimates that nearly 4 million Part D beneficiaries could be eligible.4
- Drugs used for weight loss, including anti-obesity medications, are generally excluded from Medicare. However, GLP-1 drugs are covered for Medicare when prescribed for diabetes, cardiovascular risk reduction, obstructive sleep apnea, or liver disease. The demonstration permits CMS to gather utilization data to inform future policy, including other innovation models being tested to pair negotiated GLP-1 access with nutrition and physical activity supports.5
- CMS hopes greater use of these drugs for weight management will lead to savings in the program over time as beneficiaries are healthier.
- CMS is setting guardrails to prevent the program from becoming a substitute for Part D coverage. Beneficiaries with Part D-coverable indications are excluded, and Part D plans must maintain normal coverage, formulary exception, and appeal processes. CMS will monitor Part D and Bridge data for inappropriate cost shifting, including plan practices that deny, limit, or redirect coverage to avoid Part D responsibility.
- What this means for business:
- GLP-1s are a major health benefits issue across public and private markets. Survey data of employers shows concern that GLP-1s are contributing to rising health care costs.6 As public programs test new approaches to GLP-1 access and pricing, the impact will likely shift to private plans as well, particularly if the demonstration project succeeds and becomes the basis for new CMS policy.
- https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program
- https://www.healthline.com/health/drugs/will-my-insurance-cover-glp-1-for-weight-loss#private-insurance-coverage
- https://www.kff.org/medicare/nearly-four-million-medicare-beneficiaries-could-be-eligible-for-the-temporary-medicare-glp-1-bridge-program-covering-these-drugs-for-weight-loss/
- https://www.cms.gov/priorities/innovation/innovation-models/balance
- https://www.businessgrouphealth.org/newsroom/news-and-press-releases/press-releases/2026-glp-1-survey
You already have an account with The Conference Board
Please try to login in with your email or click here if you have forgotten your password
Create An Account
- Download
- Download Newsletters & Alerts
More From This Series
Newsletters & Alerts
Supreme Court Strikes Down Major Campaign Finance Provision
July 08, 2026
Newsletters & Alerts
Judge Rules Administration’s $100,000 H-1B Visa Fee Unlawful
July 07, 2026
Newsletters & Alerts
Termination of Temporary Protected Status for Haitian and Syrian Nationals
July 02, 2026
Newsletters & Alerts
OMB Proposes Major Overhaul of Federal Grantmaking Rules
July 01, 2026
Newsletters & Alerts
Administration Requests $88 Billion in Supplemental Funding
July 01, 2026
Newsletters & Alerts
Supreme Court Upholds State Mail Voting Deadlines
July 01, 2026
View LessView More
Conference Board Sample Web Chat
